Both medications deliver meaningful results, but the numbers paint slightly different pictures
Studies, such as those published in the Journal of Clinical Endocrinology & Metabolism , highlight the multifaceted benefits of GLP-1 receptor agonists in weight management
There are several limitations to consider
Instead, we got Ozempic face, celebrity gossip, and a cultural fixation on the cosmetic outcome, while ignoring the profound metabolic and health benefits that matter far more for healthspan
reported that semaglutide accessed the brainstem, hypothalamus, and the dorsal half of the septal area, largely via small circumventricular organs, but it was not shown to cross the BBB [27]
Adding other GLP-1 agonists (semaglutide, tirzepatide) is redundant and increases side effects